Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to -$70.5 million.

  • Syndax Pharmaceuticals' Cash from Operations fell 1317.83% to -$70.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$310.9 million, marking a year-over-year decrease of 2009.39%. This contributed to the annual value of -$274.9 million for FY2024, which is 7117.14% down from last year.
  • According to the latest figures from Q3 2025, Syndax Pharmaceuticals' Cash from Operations is -$70.5 million, which was down 1317.83% from -$87.8 million recorded in Q2 2025.
  • Syndax Pharmaceuticals' Cash from Operations' 5-year high stood at $100.7 million during Q4 2021, with a 5-year trough of -$95.2 million in Q1 2025.
  • For the 5-year period, Syndax Pharmaceuticals' Cash from Operations averaged around -$41.8 million, with its median value being -$41.3 million (2023).
  • Per our database at Business Quant, Syndax Pharmaceuticals' Cash from Operations skyrocketed by 74429.02% in 2021 and then crashed by 12273.28% in 2022.
  • Over the past 5 years, Syndax Pharmaceuticals' Cash from Operations (Quarter) stood at $100.7 million in 2021, then crashed by 122.73% to -$22.9 million in 2022, then tumbled by 80.61% to -$41.3 million in 2023, then crashed by 38.79% to -$57.4 million in 2024, then dropped by 22.91% to -$70.5 million in 2025.
  • Its Cash from Operations was -$70.5 million in Q3 2025, compared to -$87.8 million in Q2 2025 and -$95.2 million in Q1 2025.